WASHINGTON – The Food and Drug Administration have approved a new, experimental drug to treat Alzheimer’s Disease.
Biogen’s medication is called Aducanumab, and it’s for mild cognitive impairment associated with the early stages of the brain wasting disease.
The decision comes seven months after all ten members of the Peripheral and Central Nervous System drugs advisory committee voted there is not enough evidence to show the drug is effective.
Some non-profits also didn’t think the medication should be approved, though, the Alzheimer’s association supported it.
It will take several months for the drug to become available for most patients. Some stakeholders have also voiced concern the drug may be too expensive.
It’s not known exactly how much it would cost patients. It’s been nearly 20 years since the agency has approved a new medication to treat the disease.